Contribute Try STAT+ Today

EpiPen may be a budget buster for some households, but new data indicates prescriptions for the allergy emergency device are outpacing last year’s figures. At the same time, though, more prescriptions were written recently for lower-cost alternatives and, as a result, last month marked the first time in three years that EpiPen’s share of prescriptions for such devices fell.

The number of prescriptions written for the auto-injector in August rose 19 percent from the same month a year ago. Overall, the number of prescriptions are up 14 percent through September, compared with the same period in 2015. In fact, there were 40 percent more prescriptions written in the first nine months of this year compared with 2013, even as the price for EpiPen was rising, according to Athenahealth, which provides technology services to physicians.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • What Mylan has successfully done is grow the market for epinephrine auto injectors. This is more important than market share because of the increased competition. Much to her critics chagrin Heather Bresch’s (negative) publicity became the rising tide that lifted all boats.

    • So, why wasn’t increasing unit sales of a high profit product enough?

      Why did the CEO decide that doubling profits wasn’t good enough, but profits needed to be increased by 4 times, 8 times, 20 times, 1000 times?

      A decade ago, the product was sold a little above cost, at a low price, with low sales volume. Today the sales volume is a hundred times and the profits per unit a hundred times, but lots of marketing costs consume that profit per unit, but still, instead of being quite profitable at a few million, a profit margin Walmart would love, the product has profits in the billions, but with no added value to any consumers, just more costs, more taxes to pay for those profits.

Comments are closed.